Male patients with TERT mutation may be more likely to benefit from immunotherapy, especially for melanoma

Genomic mutation may be key factors for sex-biased disparities in cancer diagnosis, prognosis and prediction of treatment response. Current study has revealed that sex-based dimorphism on the efficacy of immune checkpoint inhibitors (ICIs) in various cancers and confirmed that male patients can bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jia, Li, Zhaoyan, Zhang, Chenyue, Zhang, Chenxing, Wang, Haiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521545/
https://www.ncbi.nlm.nih.gov/pubmed/32915164
http://dx.doi.org/10.18632/aging.103684

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521545/
https://www.ncbi.nlm.nih.gov/pubmed/32915164
http://dx.doi.org/10.18632/aging.103684

Ejemplares similares